COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Coherus BioSciences, Inc.
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

Number of employees : 332 people.
Sales per Business
20202021Delta
Biosimilar Products475.82100%326.55100% -31.37%
USD in Million
Sales per region
20202021Delta
United States475.82100%326.55100% -31.37%
USD in Million
Managers
Name Title Age Since
Denny M. Lanfear Chairman, President & Chief Executive Officer 65 2010
McDavid Stilwell Chief Financial Officer 50 2021
Vladimir Vexler, Dr. Chief Scientific Officer 63 -
Richard L. Hameister Chief Technical Officer - 2021
Rosh Dias Chief Medical Officer - 2022
Christopher Thompson Senior Vice President-Sales - -
Michael A. Fleming Executive VP-Corporate & Competitive Strategy - -
Theresa M. LaVallee, Dr. Chief Development Officer 54 2021
Paul Reider Chief Commercial Officer - 2022
Thomas F. Fitzpatrick Chief Legal Officer - 2019
Members of the board
Name Title Age Since
Denny M. Lanfear Chairman, President & Chief Executive Officer 65 2010
Mats Wahlström Independent Director 66 2012
Ali J. Satvat Independent Director 43 2014
Kimberly J. Commins-Tzoumakas Independent Director 53 2020
Mark D. Stolper Independent Director 49 2021
Lee N. Newcomer, Dr. Independent Director 68 2022
Charles Newton Director 50 2022
Jill O'Donnell-Tormey, Dr. Director - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 77,422,970 67,526,723 87.2% 0 0.0% 87.2%
Shareholders
NameEquities%
Temasek Holdings Pte Ltd. (Investment Management) 7,381,116 9.55%
AllianceBernstein LP 5,813,624 7.52%
SSgA Funds Management, Inc. 5,164,152 6.68%
Perceptive Advisors LLC 4,695,848 6.07%
The Vanguard Group, Inc. 4,568,833 5.91%
JPMorgan Investment Management, Inc. 4,537,661 5.87%
KKR Investment Management LLC 3,055,055 3.95%
Kohlberg Kravis Roberts & Co. LP 3,036,076 3.93%
Camber Capital Management LP 2,200,000 2.84%
Aristotle Capital Boston LLC 2,192,602 2.84%
Company contact information
Coherus BioSciences, Inc.
333 Twin Dolphin Drive
Suite 600
Redwood City, CA 94065

Phone : +1.650.649.3530
Web : http://www.coherus.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Coherus BioSciences, Inc.